NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2080220018

Registered date:02/09/2005

Basic Information

Recruitment status
Health condition(s) or Problem(s) studiedRA
Date of first enrollment02/09/2005
Target sample size
Countries of recruitment
Study typeInterventional
Intervention(s)investigational material(s) Generic name etc : MRA (tocilizumab) INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : Intravenous infusion

Outcome(s)

Primary OutcomeEfficacy: Frequency of ACR improvement Safety: Frequency and severity of adverse events and adverse drug reactions
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximum<= 74age old
Gender
Include criteriaInclusion criteria (1) Diagnosis of RA based on the 1987 classification criteria of the American College of Rheumatology (ACR) (2) Between 20 and 75 years old
Exclude criteria

Related Information

Contact

Public contact
Name
Address clinical-trials@chugai-pharm.co.jp
Telephone
E-mail
Affiliation Chugai Pharmaceutical Co., Ltd.
Scientific contact
Name
Address
Telephone
E-mail
Affiliation